{"companyId":282944,"requestedLanguage":"ja","resolvedLanguage":"ja","availableLanguages":["en","ja"],"companyName":"Ionis Pharmaceuticals株式会社","headOfficeLocation":"米国カリフォルニア州カルルスバッド市ガゼルコート2855番地 92010","presidentName":"ブレット・モニア","companySummary":null,"stockCode":"IONS","currency":"USD","capital":null,"sales":null,"employees":1402,"employeesConsolidated":null,"humanCheck":false,"domains":["ionis.com"],"businessContents":["薬剤発見プラットフォーム","遺伝子編集プログラム","治療薬としてのアンチセンスオリゴヌクレオチド","前臨床アンチセンス薬剤発見","アンチセンス技術研究","アンチセンス医薬品","QALSODY®（トフェルセン）、希少遺伝性のアミオトリック症のアンチセンスオリゴヌクレオチド（ASO）治療","RNAを標的とした治療法で、ALS、アルツハイマー病を含む多くの重篤な神経疾患の治療を目指す","TRYNGOLZA®"],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://ionis.com/about-us/our-leadership","scoreAbout":37,"scoreBusiness":27,"scoreGroup":1,"scoreCustomer":3},{"detailNumber":2,"url":"https://ionis.com/","scoreAbout":0,"scoreBusiness":61,"scoreGroup":5,"scoreCustomer":2}]}